Insulet Corp (NAS:PODD)
$ 199.42 2.91 (1.48%) Market Cap: 13.97 Bil Enterprise Value: 14.41 Bil PE Ratio: 60.40 PB Ratio: 17.65 GF Score: 84/100

Insulet Corp at Canaccord Genuity Growth Conference Transcript

Aug 07, 2019 / 06:30PM GMT
Release Date Price: $142.34 (-0.55%)
Kyle William Rose
Canaccord Genuity Corp., Research Division - Senior Analyst

Continue on with the diabetes team this afternoon but transition over to insulin delivery. So next up we have Insulet, who is a top player on the insulin pump market, with what we believe is a very novel and differentiated both form factor and business model. So the company just reported -- we really think it's driven by the innovative new product cycle in DASH but also what we view as kind of a Trojan horse in the diabetes space, which is the shift to the pharmacy model. So I'm very excited

to have Insulet with us this afternoon. And presenting on behalf of Insulet is Bret Christensen,

the Chief Commercial Officer. We also have Deb Gordon, the Vice President of IR and Corporate Communications, in the audience as well.

So without any further ado, I will pass it over to Bret. Thank you.

Bret Christensen
Insulet Corporation - Executive VP & Chief Commercial Officer

Thanks, Kyle. Good afternoon, everyone. It is great to be here to talk about Insulet

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot